Neoadjuvant therapy aims to shrink tumors before surgery. However, residual disease often persists. These remaining cells can drive later relapse. Researchers therefore examine residual populations closely.
Longitudinal multi-omics profiling tracks molecular changes over time. Scientists collect samples before treatment and after therapy. They then analyze DNA, RNA, proteins and epigenetic marks together. This integrated approach reveals adaptive processes.
Furthermore, genomic sequencing detects new mutations that emerge under treatment pressure. Transcriptomic data show altered gene expression programmes. Proteomic measurements confirm functional pathway activation. Meanwhile, epigenetic profiling uncovers stable regulatory shifts that support survival.
As a result, investigators identify key adaptive resistance pathways. Residual cells frequently activate alternative signaling routes. They also enhance DNA repair capacity and modify metabolic states. In addition, immune evasion mechanisms often strengthen after therapy.
The longitudinal design strengthens causal inference. Pre-treatment profiles serve as baseline references. Post-treatment comparisons highlight therapy-driven adaptations. Therefore, researchers can distinguish true adaptive changes from pre-existing heterogeneity.
Overall, multi-omics analysis of residual disease provides mechanistic insight. It guides the development of rational combination strategies. The approach helps target the pathways that enable cancer cells to survive neoadjuvant treatment.